Partner With Us NRI

Astec Lifesciences Ltd share Price

Company details

6M Return -2.65%
1Y Return -29.20%
Mkt Cap.(Cr) 2,568.39
Volume 3,811
Div Yield 0.11%
OI Chg %
Volume 3,811

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Numbers below-par despite CMO performance…
About The Stock

    Incorporated in 1994, Astec Lifescience is primarily in production of active ingredients and intermediates for the agrochemicals segment.

    • The company operates in the space of technical as well as bulk sales. It also has a contract manufacturing business
    • Enterprise sales constitute ~80% of overall revenue while the rest comes from the CRAMS segment
Q4 FT22 Results

     Numbers were above our estimates across all parameters.

    • Reported revenue growth of 58% YoY to ₹ 272 crore, led by higher sales realisation and better volumes growth in the CMO
    • Gross margins expanded 81 bps YoY to ~39.6% while EBITDA margin were up 190 bps YoY to 24.1%
    • EBITDA was up 71% YoY to ₹ 65.5 crore
    • Adjusted PAT was up 74% YoY to ₹ 41.6 crore due to strong operational performance and higher forex gains.

Click here for full recommendation

Research view on more stocks

Agrochemicals company Astec Lifesciences announced Q1FY24 results:

  • Consolidated total income of Rs 144.6 crore in Q1FY24 as compared to Rs 187.0 crore in Q1FY23
  • Consolidated EBITDA of Rs 4.8 crore in Q1FY24 as compared to Rs 28.2 crore in Q1FY23

Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: "Astec continued to face supply glut in its enterprise products portfolio in both domestic as well as global markets. Muted volumes coupled with pricing headwinds and high costs inventories adversely impacted topline and profitability in Q1FY24.

Contract manufacturing (CMO) segment performance, however, was in line with our expectations. Revenues from CMO grew by 3.0x YoY led by new product development while profitability also improved."



Result PDF

View Other Company Results


Investment recommendation
Numbers below-par despite CMO performance…
Call Date
20 Feb 2023
Entry Price 1,387.00
Target Price 1,300.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Astec Lifesciences Ltd Stocks COMPARISION


Equity Capital: 419.37 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 16,852.71 -20,671.82
LAST 3M 52,922.55 -3,405.64
LAST 6M 58,662.39 139,660.95
LAST 12M 135,235.34 165,245.59

Astec Lifesciences Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Astec LifeSciences Ltd is a producer of agrochemicals and pharmaceutical intermediates. The company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates. They are having manufacturing facilities located at two locations in Maharashtra, India comprising of three units viz. one unit at Dombivli, Maharashtra and two units at Mahad, Maharashtra (Unit 1 and Unit 2). They are exporting their products to East Asia, Europe, Middle East, and USA. The business of the company comprises of the two major segments, namely Agrochemicals and Pharmaceuticals. Under the Agrochemical segment, the company manufactures active ingredients, intermediates and formulations. Active ingredients are sold to crop protection formulators. Intermediates are supplied to technical grade product manufacturers. Formulations are sold in bulk quantities to companies engaged in retail marketing. Under the Pharmaceutical segment, the company carries out manufacturing of intermediates which are supplied to Active Pharma Ingredients (API) manufacturers. Astec LifeSciences Ltd was incorporated on January 25, 1994 as a private limited company with the name Urshila Traders Pvt Ltd. The company was originally promoted by Reena Bagai and Avita Fernandes. Their shareholding was purchased by Ashok Hiremath and Pratap Garud on February 11, 1994. In August 19, 1994, the name of the company was changed from Urshila Traders Pvt Ltd to Astec Chemicals Pvt Ltd. In August 1994, the company started their first manufacturing unit by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. In May 2001, they were awarded ISO 9002 Certification by International Standards Certification Pty Limited, Australia. In February 18, 2002, the company entered into an agreement with Behram Chemicals Pvt Ltd with a view to expand their operations for using and operating their manufacturing facilities located at Mahad in Maharashtra. Behram Chemicals Pvt Ltd was engaged in manufacture of chemicals and pesticides with installed capacity of 130 MT. During the year 2003-04, the company expanded the total installed capacity of their units (Dombivli and Mahad) from 250 MT to 500 MT. In the year 2004, they acquired a plot of land located at Mahad, Maharashtra. In May 2005, they set up a new manufacturing facility as an Export Oriented Unit (as Unit 2), which is adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2, the company`s total installed capacity increased to 1500 MT. In March 2006, the name of the company was changed from Astec Chemicals Pvt Ltd to Astec LifeSciences Pvt Ltd. In April 2006, the company was converted into public limited company and the name was changed to Astec LifeSciences Ltd. During the year 2006-07, the company further expanded their total capacities to 2000 MT. In January 2007, they established Astec Europe in Tournai, Belgium. During the year 2007-08, the company increased the production capacity of Agro & Pharma Intermediates by 500 MT to 2500 MT In April 2007, Behram Chemicals Pvt Ltd became the subsidiary of the company by the acquisition of 65.63% equity by the company vide Share Purchase Agreement. During the year 2008-09, the company increased the production capacity of Agro & Pharma Intermediates by 300 MT to 2800 MT. They established a relationship with a major multinational for supply of one of our products into the global supply chain. During the year 2009-10, the company increased the production capacity of Agro & Pharma Intermediates by 350 MT to 3150 MT. They also introduced new measures to improve EHS performance. In December 2009, the company has bagged orders worth Rs 7 crore from Syngenta India and Nufarm, which are amongst the world`s top ten largest agrochemical manufacturing companies. In June 2010, the company entered into a long term mutually exclusive confidential contract to supply an herbicide to a multinational agrochemical major. In August 2010, the company acquired land in MIDC Mahad area admeasuring 40000 sq mtrs with a view to set up additional manufacturing facilities on the new site. In August 27, 2010, the company`s Chairman & Managing Director, Ashok V Hiremath was awarded Prestigious "Business Excellence" Award by the "Indo-Thai Entrepreneurs Summit" Bangkok, Thailand for his outstanding contribution towards progress and development of Indian Economy and Society. The Company incorporated a 100% wholly owned subsidiary, Astec CropCare Pvt. Ltd. to start the business of trading in agrochemicals and pesticides formulations to sell products. It made investments to increase the capacity of its manufacturing facility and to improvc the quality of products in Mahad. Work was started on construction of new 40000 sq m site at Mahad in Apr` 11. During the year 2012-13, the Company has set-up a new subsidiary namely, Comercializadora Agricola Agroastrachem Cia Ltda in Bagota, Columbia. During period 2015-16, Godrej Agrovet Limited acquired 45.29% of the Equity Share Capital of the Company from its ex-Promoters through an off-market transaction on 12th October, 2015 and consequently, the Company became a subsidiary of Godrej Agrovet Limited with effect from 6th November, 2015. Godrej Agrovet Limited got listed on the Stock Exchanges, viz., BSE Limited and National Stock Exchange of India Limited on 16th October, 2017. During Financial Year 2020-21, Company sold off its entire equity stake in Astec Europe Sprl (a 50.10% subsidiary of Company in Belgium, Europe), in terms of a Share Purchase Agreement executed on 31st August 2020. Accordingly, Astec Europe Sprl ceased to be a subsidiary of Company with effect from 1st September, 2020. During the Financial Year 2021-22, Company also commissioned its new herbicide plant and completed first batch of CMO product. It commercialized two new CMO products and a new production process for an enterprise product. In April 2023, Company inaugurated a state-of-the-art Research & Development (R&D) Centre, named "Adi Godrej Centre for Chemical Research and Development" in Rabale, Maharashtra.

Registered Address

GodrejOne 3rd Fl Pirojshanagar, Vikhroli (E) Eastern Exp Highw, Mumbai, Maharashtra, 400079

Tel : 91-22-25188010
Email : astecinfo:godrejastec.com
Website : http://www.astecls.com

Bigshare Services Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 533138
Book Closure Date (Month) :
BSE Group : A
ISIN : INE563J01010

FAQ’s on Astec Lifesciences Ltd Shares

You can buy Astec Lifesciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Astec Lifesciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Oct 04, 2023 12:54 PM the closing price of Astec Lifesciences Ltd was ₹ 1,310.00.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 04, 2023 12:54 PM, the market cap of Astec Lifesciences Ltd stood at ₹ 2,568.39.

The latest PE ratio of Astec Lifesciences Ltd as of Oct 04, 2023 12:54 PM is 430.66

The latest PB ratio of Astec Lifesciences Ltd as of Oct 04, 2023 12:54 PM is 0.16

The 52-week high of Astec Lifesciences Ltd is ₹ 2,288.80 while the 52-week low is ₹ 1,045.00

According to analyst recommendations, Astec Lifesciences Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app